Dimerix to Receive 'Commercial Incentives' if Expanded Kidney Disease Trial on Pediatric Patients Succeeds, Euroz Hartleys Says; Shares Fall 4%
Dimerix (ASX:DXB) may receive "commercial incentives" if its ongoing clinical trial on its DMX-200 drug for focal segmental glomerulosclerosis, a form of kidney disease, becomes successful, Euroz Hartleys said in a Thursday note.
The biotechnology firm opened its first pediatric site for the trial in Mexico, with 14 other pediatric sites set to open in the UK, the US, Argentina, and Brazil.
The investment firm said that if the pediatric segment of the study becomes successful, the drugmaker may be able to market and sell the medication to both pediatric and adult patients in key global markets, including Europe and the US.
Euroz Hartleys maintained its speculative buy rating and AU$0.86 price target on Dimerix.
Dimerix shares fell past 4% in recent Friday trade.
Price (AUD): $0.42, Change: $-0.02, Percent Change: -4.14%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。